LAS VEGAS — Clinical trials of treatments for inflammatory bowel disease (IBD) have disproportionately enrolled White people, researchers say.
These skewed demographics could result in researchers overlooking differences in how the disease and its treatments might affect other racial and ethnic groups, said Jellyana Peraza, aura soma üveg MD, a chief resident at Albert Einstein College of Medicine, New York City.
“The only way we can determine that therapies work differently in different populations is by including those populations in these clinical trials,” she told Medscape Medical News. “We think that diversity should be present, and that will answer some questions about the pathogenesis of the disease in general.”
Peraza presented the findings here at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting.
Previous studies have found that in trials of other conditions, such as cancer and cardiovascular disease, White people have been disproportionately represented. However, little research has been conducted regarding race and ethnicity in IBD trials.
To fill that gap, Peraza and colleagues analyzed data from completed trials through the US National Library of Medicine’s registry, ClinicalTrials.gov, for the period 2000 to 2020.
They found 22 trials conducted exclusively in the United States and 56 conducted in other countries that reported the race or ethnicity of participants. Fifty-four trials did not include this information.
With regard to the prevalence of IBD in White people and Asian people, these populations were overrepresented in US clinical trials. All other groups were underrepresented.
Table. IBD Prevalence and Trial Participation
|IBD Patients, %||Trial Participants, %|
The researchers calculated the odds ratio (OR) of being included in an IBD clinical trial for each group. Compared to White people, all the other groups were less likely to be included except for Asian people, who were 85% more likely to be included. These ORs were all statistically significant (P < .03) except for Hispanic people (OR, 0.81; 95% CI, 0.65 – 1.01; P = .06).
It’s not clear why Asian people are overrepresented, Peraza said. “Honestly, that was kind of surprising for us. We initially thought that could be related to where these studies were conducted, for example, if some of them were conducted on the West Coast, where maybe more Asian communities are located. However, we didn’t find any specific association between location and Asian representation.”
IBD is more prevalent among White people, although its prevalence is increasing among other groups, Peraza said. However, that is not reflected in the trials. In an analysis of data in 5-year increments, the researchers found that the participation of White and Hispanic people in IBD trials had not changed much, whereas the participation of Black people had declined, and the participation of Asian and Native American people had increased.
On the basis of work of other researchers, Peraza said that people of color are as willing to participate in trials as White people. “There is not so much a mistrust as a lack of education and a lack of access to the tertiary centers or the centers where these studies are conducted,” she said.
Clinical trial investigators should recruit more participants from community centers, and healthcare practitioners should talk about the trials with people in underrepresented groups, she said. “They should have the conversation with their patients about how these clinical trials can benefit the evolution of their diseases.”
One research center that is working hard to diversify its IBD trials is the Ohio State University IBD Center, Columbus, Ohio, said Anita Afzali, MD, its medical director.
“We have a great team that works actively on the recruitment of all patients,” she told Medscape Medical News. “Oftentimes, it just takes a little bit of education and spending time with the patient on discussing what the options are for them.”
Some research indicates that Black people with IBD are more likely to have fistulizing disease, Afzali said. “However, it doesn’t come so much of their differences in phenotype that we’re seeing but more so the differences in access to care and getting the appropriate therapy in a timely way.”
Peraza and Afzali have disclosed no relevant financial relationships.
American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting: Abstract 69. Presented October 27, 2021.
Laird Harrison writes about science, health, and culture. His work has appeared in magazines, newspapers, on public radio, and on websites. He is at work on a novel about alternate realities in physics. Harrison teaches writing at the Writers Grotto. Visit him at lairdharrison.com or follow him on Twitter: @LairdH.
For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.
Source: Read Full Article